PAR 7.69% 21.0¢ paradigm biopharmaceuticals limited..

Ann: Primary Endpoint Achieved in Phase 2 MPS VI Trial, page-40

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 7,729 Posts.
    lightbulb Created with Sketch. 6992
    Same argument could have been competently made at $4 in 2020 for PAR running out of money before it gets there. PAR has always been a cash-burning business entity. Its progressed it regulatory pathways, albeit slowly, as this result very mildly does today.

    People letting their long-term stock price arguments sway discussion of these results. Standalone, good results, but on a very small trial. Regards MPS ambitions another small successful tick in the box in its pathways.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.